Cargando…

Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease

Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population. The symptom profile after a 3(rd) mRNA vaccine dose in the predominantly immune-compromised IBD p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dalin, Debbas, Philip, Cheng, Susan, Braun, Jonathan, McGovern, Dermot P.B., Melmed, Gil Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669864/ https://www.ncbi.nlm.nih.gov/pubmed/34909797 http://dx.doi.org/10.1101/2021.12.05.21266089

Ejemplares similares

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
por: Li, Dalin, et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic
por: Melmed, Gil Y., et al.
Publicado: (2021)

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
por: Siegel, Corey A, et al.
Publicado: (2021)

1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE
por: Xu, Alexander, et al.
Publicado: (2022)

The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders
por: Li, Dalin, et al.
Publicado: (2021)

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
por: Li, Dalin, et al.
Publicado: (2022)

Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease
por: Xu, Alexander M., et al.
Publicado: (2022)

Reply
por: Melmed, Gil, et al.
Publicado: (2021)

A Paratope-Enhanced Method to Determine Breadth and Depth TCR Clonal Metrics of the Private Human T-Cell Vaccine Response after SARS-CoV-2 Vaccination
por: Li, Dalin, et al.
Publicado: (2023)

Profiling the inflammatory bowel diseases using genetics, serum biomarkers, and smoking information
por: Liu, Ruize, et al.
Publicado: (2023)

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
por: Lew, Daniel, et al.
Publicado: (2017)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease
por: Pozdnyakova, VALERIYA, et al.
Publicado: (2021)

Symptomology following mRNA vaccination against SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis
por: John, Binu V., et al.
Publicado: (2022)

Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
por: Goldwater, Marissa-Skye, et al.
Publicado: (2023)

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer
por: Figueiredo, Jane C., et al.
Publicado: (2021)

Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people
por: Hagiya, Hideharu, et al.
Publicado: (2022)

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
por: Hall, Victoria G., et al.
Publicado: (2021)

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2022)

Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
por: Yamada, Takayuki
Publicado: (2023)

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease
por: Alexander, James L, et al.
Publicado: (2021)

Antibody Responses to Third-Dose mRNA Vaccines in Nursing Home and Assisted Living Residents
por: Zhang, Ali, et al.
Publicado: (2022)

Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
por: Mengesha, Bethlehem, et al.
Publicado: (2022)

Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients
por: Kanai, Daisuke, et al.
Publicado: (2022)

Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults
por: Simone, Anthony, et al.
Publicado: (2022)

Myopericarditis Following the Third Dose of COVID-19 mRNA Vaccination: A Case Report
por: Saeed, Aamir, et al.
Publicado: (2023)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
por: Giuliano, Anna, et al.
Publicado: (2023)

Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn’s disease
por: Potdar, Alka A., et al.
Publicado: (2020)

Evolution of antibody titers after two doses of mRNA Pfizer-BioNTech vaccine and effect of the third dose in nursing home residents
por: Rodríguez-Avial, Iciar, et al.
Publicado: (2023)

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine
por: Cucunawangsih, Cucunawangsih, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

Myocarditis After the Third Dose of mRNA-1273 Coronavirus Disease 2019 (COVID-19) Vaccine
por: Kawahara, Hiroshi, et al.
Publicado: (2022)

Delayed urticaria after the third dose of mRNA COVID19 vaccine: A case series
por: Bianchi, Leonardo, et al.
Publicado: (2022)

Ulcerative injection site reaction after third COVID‐19 vaccine dose with mRNA‐1273
por: Barei, Francesca, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 Antibody Response Post Third Dose COVID-19 mRNA Vaccination at Universitas Indonesia Hospital
por: Hidayat, Rakhmad, et al.
Publicado: (2022)

Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease
por: Potdar, Alka A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9i2ah3tlcjqneue345gs7s4v4v